Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizi ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligence-based TARIO-2 model identified spatial tumor ...
Antibodies targeting cytotoxic T-lymphocyte protein 4 (CLTA-4) have faced challenges due to frequent adverse events and limited efficacy, thus pushing the search for next-generation anti-CTLA-4 ...
Clinical efficacy and safety of cadonilimab immunotherapy in patients with advanced cervical cancer: A retrospective study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”). The claims of ...
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers at Salk Institute for Biological Studies ...
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an ...
Cancer immunotherapies with immune checkpoint inhibitors are widely used to promote antitumor immune responses in a range of human cancers. However, they can also lead to inflammatory toxicities known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results